Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe’s most valuable listed company almost 5 per cent higher.

Last September, Novo Nordisk reported Phase 2 obesity study results showing ... said Wednesday that it is evaluating this drug for further clinical development in this indication.

Novo Nordisk's next-gen obesity drug, CagriSema, faces trial challenges with dosage flexibility and trial length as side-effects remain controlled. Investor skepticism arose from weaker-than-expected ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity ... obesity drug Wegovy, Martin Holst Lange, Novo Nordisk's executive vice president for development, said ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...

The company remains "quite encouraged" by the data which clearly shows better weight-loss than the company's blockbuster obesity drug Wegovy, Martin Holst Lange, Novo Nordisk's executive vice ...